“Drug Watch” Sent Back To The Drawing Board; FDA Turning To MedWatch?
This article was originally published in The Tan Sheet
Executive Summary
FDA is considering proactive communication of early adverse event reports from its MedWatch monitoring system as the agency reassesses its proposed Drug Watch website for emerging safety information